Quinone formation as a chemoprevention strategy for hybrid drugs: Balancing cytotoxicity and cytoprotection

Chemical Research in Toxicology

Volumn 20, Issue 12, 2007, Pages 1903-1912

  Dunlap, Tareisha ^a   Chandrasena, R Esala P ^a   Wang, Zhiqiang ^a   Sinha, Vaishali ^a   Wang, Zhican ^a   Thatcher, Gregory R J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; BROMIDE; ESTERASE; LUCIFERASE; MESYLIC ACID; NCX 4040; NITRATE; NITRIC OXIDE; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); THIOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CANCER THERAPY; CELL PROLIFERATION; CELL PROTECTION; CHEMOPROPHYLAXIS; COMET ASSAY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INDUCTION; GENOTOXICITY; GLUTATHIONE METABOLISM; ISOMER; LIVER CELL; MOUSE; NONHUMAN; SINGLE STRANDED DNA BREAK;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BENZOQUINONES; CATALYSIS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOPREVENTION; CYTOPROTECTION; ESTERASES; GLUTATHIONE; LIVER; LUCIFERASES; METABOLIC DETOXICATION, PHASE II; MICE; MODELS, BIOLOGICAL; NADPH DEHYDROGENASE; NITRO COMPOUNDS; RESPONSE ELEMENTS; SWINE;

EID: 38149120931     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx7002257     Document Type: Article

References (60)

1. Holtzclaw, W. D., Dinkova-Kostova, A. T., and Talalay, P. (2004) Protection against electrophile and oxidative stress by induction of phase 2 genes: The quest for the elusive sensor that responds to inducers. Adv. Enzyme Regul. 44, 335-367.
2. Talalay, P., and Dinkova-Kostova, A. T. (2004) Role of nicotinamide quinone oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates. Methods Enzymol. 382, 355-364.
3. Riegel, B., Wartman, W. B., Hill, W. T., Reeb, B. B., Shubik, P., and Stanger, D. W. (1951) Delay of methylcholanthrene skin carcinogenesis in mice by 1,2,5,6-dibenzofluorene. Cancer Res. 11, 301-303.
4. Lacassagne, A., Buu, H., and Rudali, G. (1945) Inhibition of the carcinogenic action produced by a weakly carcinogenic hydrocarbon on a highly active carcinogenic hydrocarbon. Br. J. Exp. Pathol. 26, 5-12.
5. Josephy, D. P., Guengerich, P. F., and Miners, J. O. (2005) "Phase I and Phase II" drug metabolism: Terminology that we should phase out? Drug Metab. Rev. 37, 575-580.
6. Prestera, T., and Talalay, P. (1995) Electrophile and antioxidant regulation of enzymes that detoxify carcinogens. Proc. Natl. Acad. Sci. U.S.A. 92, 8965-8969.
7. Prochaska, H. J., De Long, M. J., and Talalay, P. (1985) On the mechanisms of induction of cancer-protective enzymes: A unifying proposal. Proc. Natl. Acad. Sci. U.S.A. 82, 8232-8236.
8. Dowers, T. S., Qin, Z. H., Thatcher, G. R., and Bolton, J. L. (2006) Bioactivation of selective estrogen receptor modulators (SERMs). Chem. Res. Toxicol. 19, 1125-1137.
9. Yu, B., Dietz, B. M., Dunlap, T., Kastrati, I., Lantvit, D. L., Overk, C. R., Yao, P., Qin, Z., Bolton, J. L., and Thatcher, G. R. J. (2007) Structural modulation of reactivity/activity in design of improved benzothiophene SERMs: Induction of chemopreventive mechanisms. Mol. Cancer Ther. 6, 2418-2428.
10. Bergman, L., Beelen, M. L., Gallee, M. P., Hollema, H., Benraadt, J., and van Leeuwen, F. E. (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356, 881-887.
11. Bolton, J. L., Yu, L., and Thatcher, G. R. J. (2004) Quinoids formed from estrogens and antiestrogens. Methods Enzymol. 378, 110-123.
12. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004) Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16.
13. Petzer, J. P., Navamal, M., Johnson, J. K., Kwak, M. K., Kensler, T. W., and Fishbein, J. C. (2003) Phase 2 enzyme induction by the major metabolite of oltipraz. Chem. Res. Toxicol. 16, 1463-1469.
14. Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., and Talalay, P. (2002) Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl. Acad. Sci. U.S.A. 99, 11908-11913.
15. Bolla, M., Almirante, N., and Benedini, F. (2005) Therapeutic potential of nitrate esters of commonly used drugs. Curr. Top. Med. Chem. 5, 707-720.
16. Myers, J. K., and Widlanski, T. S. (1993) Mechanism-based inactivation of prostatic acid phosphatase. Science 262, 1451-1453.
17. Born, T. L., Myers, J. K., Widlanski, T. S., and Rusnak, F. (1995) 4-(Fluoromethyl)phenyl phosphate acts as a mechanism-based inhibitor of calcineurin. J. Biol. Chem. 270, 25651-25655.
18. Hulsman, N., Medema, J. P., Bos, C., Jongejan, A., Leurs, R., Smit, M. J., Esch, I. J., Richel, D., and Wijtmans, M. (2007) Chemical insights in the concept of hybrid drugs: The antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J. Med. Chem. 50, 2424-2431.
19. Thatcher, G. R. J., Nicolescu, A. C., Bennett, B. M., and Toader, V. (2004) Nitrates and NO release: Contemporary aspects in biological and medicinal chemistry. Free Radical Biol. Med. 37, 1122-1143.
20. Thatcher, G. R. J. (2007) Organic nitrates and nitrites as stores of NO and NO mimesis. In Radicals for Life: The Various Forms of Nitric Oxide (van Fassen, E., and Vanin, A., Eds.) Elsevier Science, Amsterdam.
21. •NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. J. Med. Chem. 34, 3242-3247.
22. Chen, C., Yu, R., Owuor, E. D., and Kong, A. N. (2000) Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch. Pharm. Res. 23, 605-612.
23. Prochaska, H. J., and Santamaria, A. B. (1988) Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: A screening assay for anticarcinogenic enzyme inducers. Anal. Biochem. 169, 328-336.
24. Song, L. L., Kosmeder, J. W., 2nd, Lee, S. K., Gerhauser, C., Lantvit, D., Moon, R. C., Moriarty, R. M., and Pezzuto, J. M. (1999) Cancer chemopreventive activity mediated by 4′-bromoflavone, a potent inducer of phase II detoxification enzymes. Cancer Res. 59, 578-585.
25. Dietz, B. M., Kang, Y. H., Liu, G., Eggler, A. L., Yao, P., Chadwick, L. R., Pauli, G. F., Farnsworth, N. R., Mesecar, A. D., van Breemen, R. B., and Bolton, J. L. (2005) Xanthohumol isolated from Humulus lupulus inhibits menadione-induced DNA damage through induction of quinone reductase. Chem. Res. Toxicol. 18, 1296-1305.
26. Kang, Y. H., and Pezzuto, J. M. (2004) Induction of quinone reductase as a primary screen for natural product anticarcinogens. Methods Enzymol. 382, 380-414.
27. Gao, J., Kashfi, K., Liu, X., and Rigas, B. (2006) NO-donating aspirin induces phase II enzymes in vitro and in vivo. Carcinogenesis 27, 803-810.
28. Dowers, T. S., Qin, Z. H., Thatcher, G. R. J., and Bolton, J. L. (2006) Bioactivation of selective estrogen receptor modulators (SERMs). Chem. Res. Toxicol. 19, 1125-1137.
29. Kwak, M. K., Wakabayashi, N., and Kensler, T. W. (2004) Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers. Mutat. Res. 555, 133-148.
30. Cuendet, M., Oteham, C. P., Moon, R. C., and Pezzuto, J. M. (2006) Quinone reductase induction as a biomarker for cancer chemoprevention. J. Nat. Prod. 69, 460-463.
31. Asher, G., Lotem, J., Cohen, B., Sachs, L., and Shaul, Y. (2001) Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc. Natl. Acad. Sci. U.S.A. 98, 1188-1193.
32. Cornblatt, B. S., Ye, L., Dinkova-Kostova, A. T., Erb, M., Fahey, J. W., Singh, N. K., Chen, M. S., Stierer, T., Garrett-Meyer, E., Argani, P., Davidson, N. E., Talalay, P., Kensler, T. W., and Visvanathan, K. (2007) Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis 28 (7), 1485-1490.
33. Zhang, D. D., and Hannink, M. (2003) Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell. Biol. 23, 8137-8151.
34. Kwak, M. K., Wakabayashi, N., Itoh, K., Motohashi, H., Yamamoto, M., and Kensler, T. W. (2003) Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem. 278, 8135-8145.
35. Kang, K. W., Lee, S. J., and Kim, S. G. (2005) Molecular mechanism of nrf2 activation by oxidative stress. Antioxid. Redox Signaling 7, 1664-1673.
36. Yuan, X., Xu, C., Pan, Z., Keum, Y. S., Kim, J. H., Shen, G., Yu, S., Oo, K. T., Ma, J., and Kong, A. N. (2006) Butylated hydroxyanisole regulates ARE-mediated gene expression via Nrf2 coupled with ERK and JNK signaling pathway in HepG2 cells. Mol. Carcinog. 45, 841-850.
37. Wakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D., Kang, M. I., Kobayashi, A., Yamamoto, M., Kensler, T. W., and Talalay, P. (2004) Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc. Natl. Acad. Sci. U.S.A. 101, 2040-2045.
38. Muscara, M. N., Lovren, F., McKnight, W., Dicay, M., del Soldato, P., Triggle, C. R., and Wallace, J. L. (2001) Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. Br. J. Pharmacol. 133, 1314-1322.
39. Cuzzolin, L., Adami, A., Degan, M., Crivellente, F., Bonapace, S., Minuz, P., and Benoni, G. (1996) Effect of single and repeated doses of a new nitroderivative of acetylsalicylic acid on platelet TXA2 production in rats. Life Sci. 58, PL207-PL210.
40. Wallace, J. L., Muscara, M. N., McKnight, W., Dicay, M., Del Soldato, P., and Cirino, G. (1999) In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016. Thromb. Res. 93, 43-50.
41. Carini, M., Aldini, G., Orioli, M., and Maffei Facino, R. (2002) In vitro metabolism of a nitroderivative of acetylsalicylic acid (NCX4016) by rat liver: LC and LC-MS studies. J. Pharm. Biomed. Anal. 29, 1061-1071.
42. Carini, M., Aldini, G., Stefani, R., Orioli, M., and Facino, R. M. (2001) Nitrosylhemoglobin, an unequivocal index of nitric oxide release from nitroaspirin: in vitro and in vivo studies in the rat by ESR spectroscopy. J. Pharm. Biomed. Anal. 26, 509-518.
43. Gao, J., Liu, X., and Rigas, B. (2005) Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 102, 17207-17212.
44. Bratasz, A., Weir, N. M., Parinandi, N. L., Zweier, J. L., Sridhar, R., Ignarro, L. J., and Kuppusamy, P. (2006) Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Proc. Natl. Acad. Sci. U.S.A. 103, 3914-3919.
45. Kashfi, K., Borgo, S., Williams, J. L., Chen, J., Gao, J., Glekas, A., Benedini, F., Del Soldato, P., and Rigas, B. (2005) Positional isomerism markedly affects the growth inhibition of colon cancer cells by NO-donating aspirin in vitro and in vivo. J. Pharmacol. Exp. Ther. 312, 978-988.
46. Baker, J. W., and Neale, A. J. (1955) Hydrolytic decomposition of esters of nitric acid. IV. Acid hydrolysis, and the effects of change in the nucleophilic reagent on the SN and ECO reactions. J. Chem. Soc. 608-615.
47. Koshy, K. M., and Robertson, R. E. (1974) α-Deuterium isotope effect for displacement of the nitrate group. J. Am. Chem. Soc. 96, 914-916.
48. Baker, J. W., and Neale, A. J. (1953) Importance of ion exchange with the solvent in kinetic studies. Nature (London) 172, 583.
49. Koshy, K. M., and Robertson, R. E. (1974) Nucleophilic displacement of the nitrate group. 1. Hydrolysis of a series of benzyl nitrates in water. Can. J. Chem. 52, 2485-2490.
50. Koshy, K. M., Robertson, R. E., Dyson, G. S., and Singh, S. (1976) The hydrolysis of substituted benzyl nitrates in water. II. Effect of ortho-substitution. Can. J. Chem. 54, 3614-3619.
51. Thatcher, G. R. J. (2007) Organic nitrates and nitrites as stores of NO. In Radicals for Life: The Various Forms of Nitric Oxide (van Fassen, E., and Vanin, A., Eds.) Elsevier Science, Amsterdam.
52. DiFabio, J., Ji, Y., Vasiliou, V., Thatcher, G. R. J., and Bennett, B. M. (2003) Role of mitochondrial aldehyde dehydrogenase in nitrate tolerance. Mol. Pharmacol. 64, 1109-1116.
53. Chiang, Y., Kresge, A. J., and Zhu, Y. (2001) Flash photolytic generation of ortho-quinone methide in aqueous solution and study of its chemistry in that medium. J. Am. Chem. Soc. 123, 8089-8094.
54. Chiang, Y., Kresge, A. J., and Zhu, Y. (2002) Flash photolytic generation and study of p-quinone methide in aqueous solution. An estimate of rate and equilibrium constants for heterolysis of the carbon-bromine bond in p-hydroxybenzyl bromide. J. Am. Chem. Soc. 124, 6349-6356.
55. Weinert, E. E., Dondi, R., Colloredo-Melz, S., Frankenfield, K. N., Mitchell, C. H., Freccero, M., and Rokita, S. E. (2006) Substituents on quinone methides strongly modulate formation and stability of their nucleophilic adducts. J. Am. Chem. Soc. 128, 11940-11947.
56. Kelder, J., Grootenhuis, P. D., Bayada, D. M., Delbressine, L. P., and Ploemen, J. P. (1999) Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 16, 1514-1519.
57. Hummel, C. W., Geiser, A. G., Bryant, H. U., Cohen, I. R., Dally, R. D., Fong, K. C., Frank, S. A., Hinklin, R., Jones, S. A., Lewis, G., McCann, D. J., Rudmann, D. G., Shepherd, T. A., Tian, H., Wallace, O. B., Wang, M., Wang, Y., and Dodge, J. A. (2005) A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats. J. Med. Chem. 48, 6772-6775.
58. Kar, S., Lefterov, I. M., Wang, M., Lazo, J. S., Scott, C. N., Wilcox, C. S., and Carr, B. I. (2003) Binding and inhibition of Cdc25 phosphatases by vitamin K analogues. Biochemistry 42, 10490-10497.
59. Nishikawa, Y., Carr, B. I., Wang, M., Kar, S., Finn, F., Dowd, P., Zheng, Z. B., Kerns, J., and Naganathan, S. (1995) Growth inhibition of hepatoma cells induced by vitamin K and its analogs. J. Biol. Chem. 270, 28304-28310.
60. Rao, C. V., Reddy, B. S., Steele, V. E., Wang, C. X., Liu, X., Ouyang, N., Patlolla, J. M., Simi, B., Kopelovich, L., and Rigas, B. (2006) Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol. Cancer Ther. 5, 1530-1538.